Get the Stockscreener App
82.85
0.11%
0.09
After Hours:
82.79
-0.06
-0.07%
Arrowhead Pharmaceuticals Inc stock is traded at $82.85, with a volume of 1.34M.
It is up +0.11% in the last 24 hours and down -7.16% over the past month.
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
See More
Previous Close:
$82.76
Open:
$83.75
24h Volume:
1.34M
Relative Volume:
0.67
Market Cap:
$11.70B
Revenue:
$622.01M
Net Income/Loss:
$-271.86M
P/E Ratio:
-38.56
EPS:
-2.1484
Net Cash Flow:
$-45.87M
1W Performance:
-4.04%
1M Performance:
-7.16%
6M Performance:
+42.60%
1Y Performance:
+178.77%
1-Day Range:
$82.36
$85.98
1-Week Range:
$80.33
$87.20
52-Week Range:
$28.12
$95.49
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
Name
Arrowhead Pharmaceuticals Inc
Sector
Industry
Phone
626-696-4702
Address
177 E COLORADO BLVD, PASADENA, CA
Compare ARWR vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARWR
Arrowhead Pharmaceuticals Inc
|
82.85 | 11.69B | 622.01M | -271.86M | -45.87M | -2.1484 |
VRTX
Vertex Pharmaceuticals Inc
|
515.44 | 130.42B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
781.49 | 81.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.39 | 61.56B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
143.97 | 54.54B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.77 | 43.59B | 742.00K | -1.37B | -1.07B | -7.0731 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-05-24 | Initiated | Goldman | Neutral |
| Dec-04-23 | Initiated | BofA Securities | Buy |
| Sep-19-23 | Initiated | Citigroup | Neutral |
| Jul-21-23 | Initiated | TD Cowen | Outperform |
| May-12-23 | Downgrade | SVB Securities | Outperform → Market Perform |
| Apr-26-23 | Initiated | SMBC Nikko | Outperform |
| Apr-12-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-11-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-19-22 | Resumed | Goldman | Buy |
| Aug-06-21 | Reiterated | Chardan Capital Markets | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| Feb-05-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-16-20 | Initiated | UBS | Buy |
| Nov-19-20 | Initiated | Citigroup | Buy |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| May-08-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-15-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-24-20 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Mar-17-20 | Initiated | Goldman | Neutral |
| Jan-21-20 | Initiated | SVB Leerink | Underperform |
| Dec-13-19 | Initiated | Oppenheimer | Perform |
| Nov-29-19 | Reiterated | Chardan Capital Markets | Buy |
| Nov-27-19 | Reiterated | B. Riley FBR | Buy |
| Nov-25-19 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-24-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-22-19 | Reiterated | Chardan Capital Markets | Buy |
| Oct-03-19 | Initiated | Robert W. Baird | Outperform |
| Sep-07-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| Sep-06-18 | Reiterated | Chardan Capital Markets | Buy |
| Aug-08-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Jul-02-18 | Reiterated | Chardan Capital Markets | Buy |
View All
Arrowhead Pharmaceuticals Inc Stock (ARWR) Latest News
Avoiding Lag: Real-Time Signals in (ARWR) Movement - Stock Traders Daily
ARWR Looks 63.8% Overvalued on GF Value™ - GuruFocus
ARWR Stock Clocks Best Day In Nearly 8 Months As Analyst Lifts Price Target On Plozasiran Data - Stocktwits
Arrowhead Pharmaceuticals, Inc. (ARWR) Latest Stock News & Headlines - finance.yahoo.com
ARWR Initiated Coverage by Citigroup -- Price Target Announced a - GuruFocus
ARWR: SHASTA-3 and SHASTA-4 Data Presented at ESC 2026 - Yahoo Finance
Arrowhead Pharmaceuticals Director Sells 11,600 Shares for $1 Million - finance.yahoo.com
Arrowhead Pharmaceuticals Inc. (ARWR) Key Financial Ratios – Valuation, Profitability & More - Value Research
Arrowhead (ARWR) Reported a 78% Lower Pancreatitis Event Rate With Plozasiran. Does the Absolute Benefit Support a Broader Label? - finance.yahoo.com
Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences - Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses SHASTA-3 and SHASTA-4 12-Month Results for Plozasiran in Severe HypertriglyceridemiaSlideshow (NASDAQ:ARWR) 2026-09-02 - Seeking Alpha
ARWR Reiterated by HC Wainwright & Co. -- Price Target Maintained at $120 - GuruFocus
Is Arrowhead Pharmaceuticals (ARWR) Undervalued As SHASTA 3 And SHASTA 4 Data Impress? - Yahoo Finance
Arrowhead Pharmaceuticals' sHTG Therapy Could Get FDA Approval by Q2 2027, RBC Says - marketscreener.com
Arrowhead’s Plozasiran Cuts Triglycerides, Pancreatitis Risk in Phase 3 Trials - Yahoo Finance
Stifel reiterates Buy rating on Arrowhead Pharma stock at $104 - Investing.com
Arrowhead’s new Redemplo findings in severe hypertriglyceridemia have analysts split - biospace.com
Arrowhead Pharmaceuticals' Plozasiran Meets Endpoints in Studies of Patients With Severe Hypertriglyceridemia - marketscreener.com
Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia - Investing News Network
Arrowhead’s plozasiran cuts pancreatitis events in Phase 3 studies (ARWR:NASDAQ) - Seeking Alpha
Could Arrowhead Pharmaceuticals (ARWR)’s Plozasiran Become the Catalyst for a Major Stock Re-rating? - finance.yahoo.com
Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of Cardiology Congress - Business Wire
Don't Ignore The Insider Selling In Arrowhead Pharmaceuticals - Moomoo
Arrowhead Pharmaceuticals director sells $173,920 in stock - Investing.com
Arrowhead Pharmaceuticals (ARWR) Director Adeoye Olukotun Sells 2,000 Shares - GuruFocus
Arrowhead (ARWR) Stock: Slides 3.28% to $86.47 in the Latest Reading; Technical Setup: the $82.15 to $90.79 Range Remains in Focus at the CloseHigh Dividend Factor - Vinanet
Arrowhead Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:ARWR - TradingView
Arrowhead (NASDAQ: ARWR) director to sell 2,000 shares - Stock Titan
Arrowhead (NASDAQ: ARWR) director to sell 11,600 shares - Stock Titan
ARWR Looks 53.4% Overvalued on GF Value™ - GuruFocus
People Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO® (plozasiran) as a New Treatment Option to Reduce Triglycerides - Arrowhead Pharmaceuticals, Inc.
ETFs Investing in Arrowhead Pharmaceuticals, Inc. Stocks - TradingView
Arrowhead Pharmaceuticals Earnings Call Signals Confident Expansion - TipRanks
Empowered Funds LLC Buys 119,202 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Avoro Capital discloses 9.64% Arrowhead Pharmaceuticals (ARWR) stake including warrants - Stock Titan
Arrowhead Pharmaceuticals, Inc.: Revenue and Earnings Analysts Forecasts Revisions | HDP1 | US04280A1007 - marketscreener.com
Why Arrowhead Pharmaceuticals (ARWR) Is Back In The Spotlight - Sahm
Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Analysis: A Biotech Gem with 24.74% Upside - DirectorsTalk Interviews
Assenagon Asset Management S.A. Grows Stock Holdings in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
How Investors Are Reacting To Arrowhead Pharmaceuticals (ARWR) Soaring Sales But Deepening Losses - simplywall.st
FY2026 Earnings Estimate for ARWR Issued By HC Wainwright - MarketBeat
Zacks Research Analysts Increase Earnings Estimates for ARWR - MarketBeat
Pacer Advisors Inc. Invests $1.50 Million in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Expected to Rise, HC Wainwright Analyst Says - marketbeat.com
Morgan Stanley Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $120 - Moomoo
Arrowhead Pharmaceuticals (ARWR) Stock Retreats As Losses Deepen Behind Phase III Progress - simplywall.st
Arrowhead Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $110.2, Implies 23% Upside - TradingView
Arrowhead Pharmaceuticals Inc (ARWR) (Q3 2026) Earnings Call Highlights: Strong Phase III Data ... - Yahoo Finance
Arrowhead Pharmaceuticals Q3 Earnings Call Highlights - marketbeat.com
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Announces Quarterly Earnings Results - MarketBeat
Arrowhead Pharmaceuticals Inc Stock (ARWR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.24%
1.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):